Skip to main content

TIGR, Biolog Pen Phenotype-Microarray R&D Collaboration

NEW YORK, Oct. 1 - Biolog today said it has licensed its new phenotype microarray technology to The Institute for Genomic Research.

 

TIGR will use the technology, with Biolog's help, "to understand and characterize" phenotypes of different bacterial strains, especially strains of Salmonella typhimurium, Streptococcus pneumoniae, Staphylococcus aureus, Synechococcus sp. and Escherichia coli.

The institute said it will conduct in-house comparative-genomics and microarray studies to interpret the data that come out of the collaboration.

 

Under the terms of the agreement, TIGR and Biolog will share certain undisclosed IP rights from any new discoveries identified using the PM technology. The partners have also agreed to exclusively license any discoveries that might have potential commercial applications.

 

"We hope to be able to complement our existing genome sequencing, bioinformatic and expression microarray capabilities with Biolog's phenotype microarray technology to further our understanding of microbial cell function," said Ian Paulsen, the TIGR faculty member leading the phenotype microarray analyses.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.